GMO International Quality ETF (QLTI)

QLT Inc. establishes sales force in the United States

- QLT Ophthalmics, Inc. will market Visudyne(R) to retinal specialists across the U.S.- VANCOUVER, Dec. 22 /PRNewswire-FirstCall/ -- QLT Inc...

QLT initiates Phase Ib study of QLT091001 in Leber Congenital Amaurosis

VANCOUVER, Dec. 15 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced that it has initiated...

6-month results from EVEREST study evaluating Visudyne(R) therapy in patients with polypoidal choroidal vasculopathy

VANCOUVER, Dec. 9 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") welcomed the 6-month results from the...

QLT announces MGH litigation settlement

VANCOUVER, Nov. 25 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced the settlement of its...

QLT announces Toronto Stock Exchange approval of share repurchase program

VANCOUVER, Oct. 28 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT") announced that the Toronto Stock Exchange ("TSX") has...

QLT Announces Share Repurchase Program

VANCOUVER, Oct. 27 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced that its board of...

QLT announces third quarter results for 2009

QLT SEPARATELY ANNOUNCES SHARE REPURCHASE PROGRAM VANCOUVER, Oct. 27 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the...

QLT Gets Exclusive U.S. Rights To Visudyne

QLT Inc. (QLTI) will soon have exclusive U.S. sales and marketing rights to Visudyne after reaching a restructured agreement with Novartis Pharma...

QLT restructures Visudyne(R) agreement

RECEIVES EXCLUSIVE U.S. RIGHTS AND WILL RECEIVE A ROYALTY ON SALES OUTSIDE THE U.S. VANCOUVER, Oct. 19 /PRNewswire-FirstCall/ -- QLT Inc...

QLT announces sale of QLT USA, Inc. for up to US$230 million

VANCOUVER, Oct. 1 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced that it has completed the...

QLT announces receipt of a CDN$45.3 million tax refund

VANCOUVER, Sept. 8 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced that it has received an...

QLT Announces Second Quarter Results for 2009

QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System

QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination ther

VANCOUVER, June 15 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced that twelve-month primary analysis results from...

QLT announces positive results from the evaluation of Visudyne(R) combination therapy

VANCOUVER, June 2 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced positive twelve-month primary analysis results...